Free Trial

Compass Pathways (NASDAQ:CMPS) Upgraded to "Hold" at Wall Street Zen

Compass Pathways logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Compass Pathways from “sell” to “hold.” Despite the change, analysts’ overall consensus remains “Moderate Buy,” with an average price target of $23.14.
  • Other firms cited in the report maintained or issued mostly positive ratings, including “buy” and “outperform” recommendations; BTIG set a $25 price target.
  • Compass reported a quarterly loss of $0.31 per share, beating analysts’ estimate of a $0.39 loss. The stock opened at $9.01, within a 12-month range of $4.88 to $15.87.
  • Five stocks we like better than Compass Pathways.

Compass Pathways (NASDAQ:CMPS - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Monday, Wall Street Zen reports.

CMPS has been the subject of several other research reports. Royal Bank Of Canada restated an "outperform" rating on shares of Compass Pathways in a research report on Wednesday, November 4th. Jefferies Financial Group reiterated a "buy" rating on shares of Compass Pathways in a research report on Monday, November 9th. BTIG Research reiterated a "buy" rating and set a $25.00 price objective on shares of Compass Pathways in a research note on Tuesday, November 3rd. Morgan Stanley lifted their price objective on Compass Pathways from $17.00 to $18.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Finally, B. Riley Financial lifted their price objective on Compass Pathways from $17.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Compass Pathways currently has an average rating of "Moderate Buy" and a consensus price target of $23.14.

Read Our Latest Analysis on Compass Pathways

Compass Pathways Stock Performance

NASDAQ:CMPS opened at $9.01 on Monday. The firm has a market capitalization of $1.28 billion, a PE ratio of -2.58 and a beta of 2.43. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.35. Compass Pathways has a 12-month low of $4.88 and a 12-month high of $15.87. The firm has a 50-day moving average price of $11.89 and a 200 day moving average price of $10.46.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.08. Research analysts anticipate that Compass Pathways will post -0.78 earnings per share for the current fiscal year.

Institutional Trading of Compass Pathways

Several hedge funds have recently modified their holdings of the company. HighVista Strategies LLC grew its position in Compass Pathways by 37.1% during the 3rd quarter. HighVista Strategies LLC now owns 508,780 shares of the company's stock worth $6,329,000 after acquiring an additional 137,660 shares during the last quarter. Smith Moore & CO. acquired a new stake in Compass Pathways during the 3rd quarter valued at $157,000. Creek Drive Management Group LLC increased its holdings in Compass Pathways by 91.9% during the 3rd quarter. Creek Drive Management Group LLC now owns 1,328,000 shares of the company's stock valued at $16,520,000 after purchasing an additional 636,000 shares in the last quarter. ACT Capital Partners L.P. bought a new position in Compass Pathways in the 3rd quarter valued at $567,000. Finally, Lisanti Capital Growth LLC bought a new position in Compass Pathways in the 3rd quarter valued at $2,468,000. Institutional investors and hedge funds own 46.19% of the company's stock.

Compass Pathways Company Profile

(Get Free Report)

Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.

Further Reading

Analyst Recommendations for Compass Pathways (NASDAQ:CMPS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Compass Pathways Right Now?

Before you consider Compass Pathways, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Pathways wasn't on the list.

While Compass Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines